Cytochrome P450 regulation and drug biotransformation during inflammation and infection

被引:141
作者
Renton, KW [1 ]
机构
[1] Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada
关键词
D O I
10.2174/1389200043335559
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The expression of cytochrome P450 and related biotransformation is altered during the operation of host defense mechanisms. This has major implications in inflammation and infection when the capacity of the liver and other organs to handle drugs is severely compromised. In most cases individual cytochrome P450 forms are down regulated at the level of gene transcription with a resulting decrease in the corresponding mRNA, protein and enzyme activity. The loss in drug metabolism is channeled predominantly through the production of cytokines which ultimately modify specific transcription factors. Other proposed mechanisms that apply to specific cytochrome P450s involve post translational steps including enzyme modification and increased degradation. When inflammatory responses are confined to the brain there is a loss of cytochrome P450 not only in the brain but also in peripheral tissues. This involves a yet to be identified mode of signaling between the brain and periphery but it does involve the production of cytokines from a peripheral source. In clinical medicine there are numerous examples of a decreased capacity to handle drugs during infections and disease states that involve an inflammatory component. This often results in altered drug responses and increased toxicities. Inflammation mediated alterations in the metabolism of endogenous compounds can lead to altered physiology. Changes in drug handling capacity during inflammation/injection will continue to be one of the many factors that complicate therapeutics.
引用
收藏
页码:235 / 243
页数:9
相关论文
共 122 条
[71]  
MORGAN ET, 1989, MOL PHARMACOL, V36, P699
[72]   SELECTIVE SUPPRESSION OF CYTOCHROME-P-450 GENE-EXPRESSION BY INTERLEUKIN-1 AND INTERLEUKIN-6 IN RAT-LIVER [J].
MORGAN, ET ;
THOMAS, KB ;
SWANSON, R ;
VALES, T ;
HWANG, J ;
WRIGHT, K .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1994, 1219 (02) :475-483
[73]   Mechanisms of cytochrome P450 regulation by inflammatory mediators [J].
Morgan, ET ;
Li-Masters, T ;
Cheng, PY .
TOXICOLOGY, 2002, 181 :207-210
[74]   PRETRANSLATIONAL DOWN-REGULATION OF CYTOCHROMES P450 2C11 AND 3A2 IN MALE-RAT LIVER BY TUMOR-NECROSIS-FACTOR-ALPHA [J].
NADIN, L ;
BUTLER, AM ;
FARRELL, GC ;
MURRAY, M .
GASTROENTEROLOGY, 1995, 109 (01) :198-205
[75]   Role of cytokines in the lipopolysaccharide-evoked depression of cytochrome P450 in the brain and liver [J].
Nicholson, TE ;
Renton, KW .
BIOCHEMICAL PHARMACOLOGY, 2001, 62 (12) :1709-1717
[76]   The role of cytokines in the depression of CYP1A activity using cultured astrocytes as an in vitro model of inflammation in the central nervous system [J].
Nicholson, TE ;
Renton, KW .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (01) :42-46
[77]  
NICHOLSON TE, 2001, UNPUB
[78]   Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome [J].
O'Neil, WM ;
Gilfix, BM ;
Markoglou, N ;
Di Girolamo, A ;
Tsoukas, CM ;
Wainer, IW .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (03) :231-240
[79]   What changes drug metabolism in critically ill patients .2. Serum inhibits the metabolism of midazolam in human microsomes [J].
Park, GR ;
Miller, E ;
Navapurkar, V .
ANAESTHESIA, 1996, 51 (01) :11-15
[80]  
PARKINSON A, 1982, DRUG METAB DISPOS, V10, P579